Objective To explore non-valvular atrial fibrillation elderly warfarin anticoagulation efficacy and safety. Methods July 2013-July 2015 65 patients ≥80 years of age treated with non-valvular atrial fibrillation patients as research subjects were randomly divided into two groups, namely warfarin and aspirin were given Hua warfarin antico-agulation therapy with aspirin therapy, compared two groups of efficacy and safety. Results Of the end of the aspirin group event rate (28.13%) was significantly higher than in the warfarin group endpoint event rate (6.06%), the differ-ence was statistically significant (P<0.05). The incidence of bleeding in the aspirin group (12.50%) and bleeding rates (15.15%) warfarin group had no significant difference not statistically significant (P> 0.05). Conclusion For elderly non-valvular atrial fibrillation by warfarin therapy treatment can effectively reduce the incidence of endpoint events, and the treatment of the relatively low incidence of bleeding, effective, safe, it has a certain application value.%目的：探究高龄非瓣膜病性房颤应用华法林抗凝治疗的疗效及安全性。方法选取2013年7月一2015年7月收治的65例≥80岁非瓣膜病性房颤患者作为研究对象，将其随机分为两组，分别是华法林组与阿司匹林组，分别给予华法林抗凝治疗与阿司匹林药物治疗，对比两组疗效及安全性。结果阿司匹林组的终点事件发生率(28.13%)明显高于华法林组的终点事件发生率(6.06%)，其差异有统计学意义(P〈0.05)。阿司匹林组的出血发生率(12.50%)与华法林组的出血发生率(15.15%)，差异无统计学意义(P〉0.05)。结论针对高龄非瓣膜病性房颤中通过华法林抗凝治疗方式治疗，能够有效降低终点事件的发生率，并且治疗中出血发生率相对较低，疗效好，安全性高，具有一定的推广应用价值。
展开▼
